0001193125-23-038884.txt : 20230214 0001193125-23-038884.hdr.sgml : 20230214 20230214153201 ACCESSION NUMBER: 0001193125-23-038884 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TFF Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001733413 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824344737 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-91311 FILM NUMBER: 23627987 BUSINESS ADDRESS: STREET 1: 2600 VIA FORTUNA, SUITE 360 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 737-802-1973 MAIL ADDRESS: STREET 1: 2600 VIA FORTUNA, SUITE 360 CITY: AUSTIN STATE: TX ZIP: 78746 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Lung Therapeutics, Inc. CENTRAL INDEX KEY: 0001611241 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461383209 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: P.O. BOX 150183 CITY: AUSTIN STATE: TX ZIP: 78715 BUSINESS PHONE: 512-809-8549 MAIL ADDRESS: STREET 1: P.O. BOX 150183 CITY: AUSTIN STATE: TX ZIP: 78715 SC 13G/A 1 d388620dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

 

 

TFF Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001

(Title of Class of Securities)

87241J104

(CUSIP Number)

12/31/2022

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

  1    

  NAME OF REPORTING PERSON

 

  Lung Therapeutics, Inc.

 

  I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

  46-1383209

  2    

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

  (a)  ☐        (b)  ☐

 

  3    

  SEC USE ONLY

 

  4    

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  State of Texas

NUMBERS OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH:

     5     

  SOLE VOTING POWER

 

  773,000

  6     

  SHARED VOTING POWER

 

  0

  7     

  SOLE DISPOSITIVE POWER

 

  773,000

  8     

  SHARED DISPOSITIVE POWER

 

  0

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  773,000

10    

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

 

  ☐

11    

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

  2.1%

12    

  TYPE OF REPORTING PERSON (See Instructions)

 

  CO

 

- 2 -

SCHEDULE 13G

Item 1.

(a) Name of Issuer:       TFF Pharmaceuticals, Inc.

(b) Address of Issuer’s Principal Executive Offices:

1751 River Run, Suite 400

Fort Worth, Texas 76107

Item 2.

(a) Name of Person Filing:       Lung Therapeutics, Inc.

(b) Address of Principal Business Office or, if None, Residence:

3801 S. Capital of Texas Hwy, Suite 330 Austin, Texas 78704

(c) Citizenship:       State of Texas

(d) Title of Class of Securities: Common Stock, par value $0.001                

(e) CUSIP Number:                 87241J104

Item 3.

Not Applicable.

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: 773,000 shares of common stock

(b) Percent of class: 2.1%

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote: 773,000

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 773,000

(iv) Shared power to dispose or to direct the disposition of: 0

 

- 3 -

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following   ☒.

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not Applicable.

Item 10. Certifications

Not Applicable.

 

- 4 -

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  February 14, 2023

(Date)
Lung Therapeutics, Inc.
By:  

/s/ Brian Windsor

  Name: Brian Windsor
  Title: President and CEO

 

- 5 -